Table 1. Meta-analyses included in this analysis.

Intervention	No. of Data Sources	No. of Experiments	No. of Animals	Reported Effect Size (95%Cl)
Estrogens [10]	27	99	1,452	26.7% (20.4%–33.0%)
FK506 [12]	27	96	1,596	32.0% (27.8%–36.3%)
Growth factors	70	128	1,750	29.7% (25.9%–33.4%)
Hypothermia [40]	98	222	3,256	43.5% (40.1%–47.0%)
IL1-RA [21]	23	44	784	38.2% (31.2%–45.1%)
Melatonin [13]	12	29	443	42.1% (35.7%–48.5%)
Minocycline	8	25	535	30.9% (24.1%–37.6%)
Nicotinamide [11]	11	57	719	29.2% (23.0%–35.5%)
NOS donors [19]	17	40	483	21.4% (13.7%–29.1%)
NOS inhibitors [41]	52	148	1,998	22.2% (17.1%–27.3%)
NXY-059 [14]	9	29	408	43.8% (34.7%–52.8%)
Piracetam and related compounds [18]	5	14	197	29.6% (16.1%–44.4%)
Stem cells	46	112	1,352	29.6% (23.7%–35.4%)
Tirilazad [16]	18	34	544	31.9% (23.1%–40.7%)
tPA [15]	105	256	4,029	22.5% (19.2%–25.9%)
Other thrombolyics	12	26	410	46.6% (35.7%–57.5%)
Pooled analysis	525 *	1,359	19,956	31.3% (29.7%–32.8%)

*Fifteen data sources were represented in more than one review and are included only once in the pooled analysis.